Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02756754
Other study ID # 15 7833 08
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 7, 2016
Est. completion date May 10, 2019

Study information

Verified date July 2019
Source University Hospital, Toulouse
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to evaluate the novel use of adrenal radiofrequency ablation on a prospective cohort of patients with primary aldosteronism and unilateral adrenal adenoma concerning the efficacy on blood pressure control. The safety of the procedure is one of the secondary outcomes.


Description:

The prevalence of hypertension dramatically increased. Although most cases of hypertension are idiopathic, some cases have an identifiable cause. Primary Aldosteronism (PA) is the most common cause of secondary hypertension and can be cured by surgery if PA is due to unilateral unique adrenal adenoma. Then this cause is worth identifying it. The surgery despite its minimally invasive nature is limited by the need for general anesthesia, the risk of vascular or visceral injuries, hematomas and all the adrenal gland is mostly removed. Imaged-guided percutaneous adrenal radiofrequency ablation (ARF) offers a less invasive alternative therapeutic option. This local therapy is employed to treat solid neoplasms whereas its application on functional adrenal adenoma is less documented and only a few case series with limited sample size are published. The impact on blood pressure control is not clearly reported. ARF ablation works by delivering a high-frequency alternating current through a needle electrode. An ionic agitation occurs and generates frictional heat for cell destruction at a predictable temperature and volume. Patients with a conventional documented PA due to unilateral adrenal nod who consented to the study were hospitalized. Patients with PA due to an aldosterone-producing adenoma are included in the study.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date May 10, 2019
Est. primary completion date October 4, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- hypertension confirmed with ambulatory blood pressure monitoring

- primary aldosteronism demonstrated by hormonal assays: active renin (pg/ml) or plasma renin activity (ng/ml/h) and plasma aldosterone measured twice at baseline after an overnight fast, in sitting or recumbent position

- selective adrenal venous sampling after 40 years of age

- unilateral adrenal nod on CT scan <4cm

- adrenal radiofrequency ablation procedure of judged technically possible by radiologists

Exclusion Criteria:

- bilateral adrenal nods

- primary aldosteronism due to bilateral adrenal hyperplasia or macronodular hyperplasia

- lack of documented primary aldosteronism

- maximum tumor diameter greater than 4 cm

- Cushing syndrome or Pheochromocytoma

- when adrenal venous sampling is refused by the patient

- coagulopathy

- pregnant women

- patient with potentially inaccessible nodule

Study Design


Intervention

Device:
Radiofrequency ablation
The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored.

Locations

Country Name City State
France CHU Bordeaux Bordeaux
France CHU de Toulouse Toulouse

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary mean day-time systolic/diastolic blood pressure mean day-time systolic/diastolic blood pressure <135/85 mmHg at six months assessed by ambulatory blood pressure monitoring without antihypertensive treatment or a decrease of daytime systolic blood pressure of 20 mmHg and of diastolic blood pressure of 10 mmHg between baseline and 6 months 6 months
Secondary day-time systolic and diastolic blood pressure To assess a decrease of day-time systolic blood pressure of 20 mmHg and of diastolic blood pressure of 10 mmHg between baseline and 6 months 6 months
Secondary mean 24 hours systolic/diastolic blood pressure mean 24 hours systolic/diastolic blood pressure <130/80 mmHg at six months assessed by ambulatory blood pressure monitoring without antihypertensive treatment 6 months
Secondary mean day-time ambulatory blood pressure mean day-time ambulatory blood pressure changes assessed by ambulatory blood pressure monitoring between baseline and 6 months 6 months
Secondary mean night-time ambulatory blood pressure mean night-time ambulatory blood pressure changes assessed by ambulatory blood pressure monitoring between baseline and 6 months 6 months
Secondary mean 24 hour ambulatory blood pressure changes assessed by ambulatory blood pressure mean 24 hour ambulatory blood pressure changes assessed by ambulatory blood pressure monitoring between baseline and 6 months 6 months
Secondary casual systolic blood pressure / diastolic blood pressure casual systolic blood pressure / diastolic blood pressure <140/90 mmHg after adrenal radiofrequency ablation, at six months without antihypertensive treatment 6 months
Secondary decrease of casual systolic blood pressure decrease of casual systolic blood pressure of 20 mmHg and of casual diastolic blood pressure of 10 mmHg between baseline and 6 months 6 months
Secondary mean daytime ambulatory blood pressure changes assessed by self-measurement mean daytime ambulatory blood pressure changes assessed by self-measurement of blood pressure monitoring between baseline and 6 months 6 months
Secondary antihypertensive agents number of antihypertensive agents at 6 months after adrenal radiofrequency ablation 6 months
Secondary kalemia evaluation of kalemia at month 1 and month 6 6 months
Secondary CT Scan description of the CT scan aspect of the adrenal gland after adrenal radiofrequency ablation 6 months
Secondary post-operative complications post-operative complications including retroperitoneal hematoma, pneumothorax, pain, infection 6 months
Secondary cost-effectiveness cost-effectiveness radiofrequency ablation 6 months
See also
  Status Clinical Trial Phase
Completed NCT02885662 - Study of CS-3150 in Patients With Primary Aldosteronism N/A
Withdrawn NCT02096939 - Microvascular Function in Primary Aldosteronism N/A
Completed NCT01728493 - Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment N/A
Recruiting NCT06228677 - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting NCT06047912 - Screening for Primary Aldosteronism in Hypertension With 24-hour URinary aLdosterone
Recruiting NCT04991961 - Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Screening for Primary Aldosteronism
Recruiting NCT05405101 - Randomised Trial Comparing Thermal Ablation With Adrenalectomy in the Treatment of Unilateral Asymmetric PA N/A
Recruiting NCT05501080 - The Effect of SAAE on Ventricular Remodeling in PA Patients N/A
Recruiting NCT05973604 - Prevalence of Primary Aldosteronism in Atrial Fibrillation
Recruiting NCT05826080 - Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism
Completed NCT04179019 - Calcium Channel Blockade in Primary Aldosteronism Phase 2
Completed NCT03500120 - Diagnostic Accuracy of Seated Saline Suppression Test for Primary Aldosteronism
Recruiting NCT04213963 - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Completed NCT05435703 - Renal Cysts and Primary Aldosteronism
Recruiting NCT02945904 - IS Metomidate PET-CT Superior to Adrenal Venous Sampling in Predicting Outcome From Adrenalectomy in Patients With Primary Hyperaldosteronism
Enrolling by invitation NCT02257450 - Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study N/A
Recruiting NCT05561361 - The Effect of SAAE on Vascular Endothelial Function in PA Patients
Completed NCT03398785 - Adrenal Artery Ablation Treats Primary Aldosteronism Phase 3
Recruiting NCT04428827 - Outcome of Patients With Primary Aldosteronism
Recruiting NCT03224312 - Chongqing Primary Aldosteronism Study